Item 7.01 Regulation FD Disclosure

Mersana Therapeutics, Inc. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation (the "Presentation") is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.




 Item 8.01 Other Events.

On January 10, 2020, the Company issued a press release providing an update on the Company's business and announcing the Company's strategic priorities and goals for 2020 and beyond. The Company's press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit No.                               Description

  99.1          Corporate slide presentation of Mersana Therapeutics, Inc., dated
              January 10, 2020
  99.2          Press Release by Mersana Therapeutics, Inc., on January 10, 2020

© Edgar Online, source Glimpses